Lexaria Bioscience (LEXX) Operating Expenses (2017 - 2026)
Lexaria Bioscience (LEXX) posted Operating Expenses of $2.0 million for Q2 2026, up 35.46% sequentially from $1.5 million in Q1 2026, and down 49.19% YoY from $3.9 million in Q2 2025.
Lexaria Bioscience (LEXX) Operating Expenses (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Operating Expenses for 10 years, with the latest figure at $2.0 million in Q2 2026.
- Quarterly Operating Expenses fell 49.19% year-over-year to $2.0 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $7.9 million (down 34.2% YoY) and the FY2025 annual result came in at $12.6 million, up 102.56% from the prior year.
- Operating Expenses grew to $2.0 million in Q2 2026 per LEXX's latest filing, from $1.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $3.9 million in Q2 2025 and troughed at $813005.0 in Q1 2024.
- A 5-year average of $2.0 million and a median of $1.8 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 259.78% in 2025, then tumbled 49.68% in 2026.
- Over 5 years, Operating Expenses stood at $1.8 million in 2022, then decreased by 27.67% to $1.3 million in 2023, then jumped by 123.39% to $2.9 million in 2024, then slumped by 45.21% to $1.6 million in 2025, then rose by 26.7% to $2.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $2.0 million, $1.5 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 1.99 Mn |
| Feb 28, 2026 | 1.47 Mn |
| Nov 30, 2025 | 1.57 Mn |
| Aug 31, 2025 | 2.86 Mn |
| May 31, 2025 | 3.92 Mn |
| Feb 28, 2025 | 2.93 Mn |
| Nov 30, 2024 | 2.87 Mn |
| Aug 31, 2024 | 2.29 Mn |
| May 31, 2024 | 1.83 Mn |
| Feb 29, 2024 | 813,005.00 |
| Nov 30, 2023 | 1.29 Mn |
| Aug 31, 2023 | 1.14 Mn |
| May 31, 2023 | 2.47 Mn |
| Feb 28, 2023 | 1.34 Mn |
| Nov 30, 2022 | 1.78 Mn |
| Aug 31, 2022 | 818,448.00 |
| May 31, 2022 | 2.50 Mn |
| Feb 28, 2022 | 1.47 Mn |
| Nov 30, 2021 | 2.01 Mn |
| Aug 31, 2021 | 1.31 Mn |